Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 1.58% | 583.92% | |||
| Gross Profit | -1.58% | -583.92% | |||
| SG&A Expenses | 20.48% | -0.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.41% | 5.66% | |||
| Operating Income | -5.41% | -5.66% | |||
| Income Before Tax | -6.99% | -8.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.05% | -8.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.05% | -8.25% | |||
| EBIT | -5.41% | -5.66% | |||
| EBITDA | -7.16% | -5.47% | |||
| EPS Basic | -6.66% | -7.86% | |||
| Normalized Basic EPS | -12.32% | -7.86% | |||
| EPS Diluted | -6.66% | -7.22% | |||
| Normalized Diluted EPS | -12.32% | -7.86% | |||
| Average Basic Shares Outstanding | 0.37% | 0.37% | |||
| Average Diluted Shares Outstanding | 0.37% | 0.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
